Disease relevance of Seocalcitol

• Seocalcitol is well tolerated in pancreatic cancer but has no objective anti-tumour activity in advanced disease [1].
• Seocalcitol was well tolerated; the most frequent toxicity was hypercalcaemia and related symptoms [2].
• Cessation of treatment or administration of a lower dose (1microg/kg twice weekly) reversed hypercalcemia, hypercalciuria and weight loss induced by high dose Seocalcitol [3].
• Moreover, a promising phase I study with the vitamin D analogue Seocalcitol (EB 1089) in patients with advanced breast and colon cancer has already been carried out and more clinical trials evaluating the clinical effectiveness of EB 1089 in other cancer types are in progress (Mørk Hansen et al. [2000a]) [4].

High impact information on Seocalcitol

• Similar to malignant plasma cells, all PEL samples tested express the vitamin D receptor and are sensitive to the vitamin D analogue drug EB 1089 (Seocalcitol) [5].
• Differential skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-dihydroxyvitamin D3 and its analog, seocalcitol (EB1089) [6].
• A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma [2].
• Seocalcitol, a vitamin D analogue, induces differentiation and inhibits growth in cancer cell lines and in vivo [2].
• Bioavailability of Seocalcitol IV: Evaluation of Lymphatic Transport in Conscious Rats [7].

Biological context of Seocalcitol

• Seocalcitol (EB1089), a vitamin D analogue, can inhibit growth, induce differentiation and induce apoptosis of cancer cell lines in vitro and can also inhibit growth of pancreatic cancer xenografts in vivo [1].
• Assuming that the liver/serum concentration ratio is the same in rats and humans, the concentration of seocalcitol in the human liver is expected to be higher than the concentration resulting in more than 50% inhibition of cancer cell proliferation, and thus pharmacologically effective in HCC [8].
• Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig [9].
• 3. In rat, the pharmacokinetic profile of Seocalcitol (Cmax, AUC, Tmax, T(1/2)) was the same after single and oral administration [9].

Associations of Seocalcitol with other chemical compounds

• Therefore, calcitriol and seocalcitol with MCT may have therapeutic potential for canine bladder cancer [10].

References